In its Oct. 29 results release, Ono Pharmaceutical Co., Ltd. reported an 11.2% first-half operating-profit rise as revenue fell 9.6% in the six months through Sept. 30, 2026.
Revenue came to ¥232.5 billion, a 9.6% year-over-year decrease. Operating profit was ¥57.91 billion, while core operating profit reached ¥73.63 billion, 5.1% higher than in the comparable period.
Ono's basic earnings per share for the half came to ¥95.60 under International Financial Reporting Standards (IFRS).
Ono projects ¥455 billion in consolidated revenue for fiscal 2026, which ends March 31, 2027. Its operating-profit estimate for the year is ¥94 billion on an IFRS basis.
